A task-oriented circuit training in multiple sclerosis: a feasibility study

  • Sofia Straudi1, 2Email author,

    Affiliated with

    • Carlotta Martinuzzi1Email author,

      Affiliated with

      • Claudia Pavarelli1,

        Affiliated with

        • Amira Sabbagh Charabati1Email author,

          Affiliated with

          • Maria Grazia Benedetti3,

            Affiliated with

            • Calogero Foti2,

              Affiliated with

              • Michela Bonato1Email author,

                Affiliated with

                • Eleonora Zancato1Email author and

                  Affiliated with

                  • Nino Basaglia1

                    Affiliated with

                    BMC Neurology201414:124

                    DOI: 10.1186/1471-2377-14-124

                    Received: 27 March 2014

                    Accepted: 30 May 2014

                    Published: 7 June 2014



                    The aim of this study was to evaluate the safety, feasibility and preliminary effects of a high-intensity rehabilitative task-oriented circuit training (TOCT) in a sample of multiple sclerosis (MS) subjects on walking competency, mobility, fatigue and health-related quality of life (HRQoL).


                    24 MS subjects (EDSS 4.89 ± 0.54, 17 female and 7 male, 52.58 ± 11.21 years, MS duration 15.21 ± 8.68 years) have been enrolled and randomly assigned to 2 treatment groups: (i) experimental group received 10 TOCT sessions over 2 weeks (2 hours/each session) followed by a 3 months home exercise program, whereas control group did not receive any specific rehabilitation intervention. A feasibility patient-reported questionnaire was administered after TOCT. Functional outcome measures were: walking endurance (Six Minute Walk Test), gait speed (10 Meter Walk Test), mobility (Timed Up and Go test) and balance (Dynamic Gait Index). Furthermore, self-reported questionnaire of motor fatigue (Fatigue Severity Scale), walking ability (Multiple Sclerosis Walking Scale – 12) and health-related quality of life (Multiple Sclerosis Impact Scale – 29) were included. Subjects’ assessments were delivered at baseline (T0), after TOCT (T1) and 3 months of home-based exercise program (T2).


                    After TOCT subjects reported a positive global rating on the received treatment. At 3 months, we found a 58.33% of adherence to the home-exercise program. After TOCT, walking ability and health-related quality of life were improved (p < 0.05) with minor retention after 3 months. The control group showed no significant changes in any variables.


                    This two weeks high-intensity task-oriented circuit class training followed by a three months home-based exercise program seems feasible and safe in MS people with moderate mobility impairments; moreover it might improve walking abilities.

                    Trial registration



                    Task oriented Rehabilitation Mobility Multiple sclerosis


                    Multiple sclerosis (MS) is a chronic and progressive neurologic disease that commonly affects young adults worldwide and it represents a major cause of disability over time [1, 2]. In this population gait and mobility impairments could have a negative impact on personal activities not only restricted to motor domains and participation but also to quality of life [3, 4]. There are several studies showing a benefit of physical therapy on walking function, mobility [59] and fatigue [1012]; for this reason recent reviews and international guidelines recommend exercise for MS population [13, 14]. Nonetheless, the task-oriented circuit training (TOCT) approach hasn’t been studied enough in people with MS (PwMS) and gait and mobility disorders. TOCT is based on workstations that reproduce physical activities that the subject usually performs during daily living (i.e. walking, climbing stairs, maintain balance) with the aim of promoting motor learning and task retention. In addition, a major characteristic of this rehabilitative intervention is the exercise intensity that, compared to a conventional physiotherapy session, is nearer to the number of repetitions needed to achieve and maintain motor learning of these movements [15]. Moreover, TOCT has been designed for small groups of subjects requiring only one physiotherapist compared with conventional rehabilitation session in which the ratio is 1:1, giving also the advantage of reducing costs of rehabilitation. Previous studies [16, 17] have shown that TOCT is a good method to improve locomotor function and mobility in stroke survivors.

                    The rationale of our study is based on growing evidences [18] that demonstrate how human adult brain is capable of significant adaptations providing that the quantity (duration and frequency) and quality (task-specificity) of interventions are appropriate to facilitate enhanced neural reorganization and upper limb motor recovery in chronic stroke survivors [19]. Also, recent neuroimaging studies highlighted how adaptive brain plasticity [20, 21] and motor learning [22] are preserved even in progressive MS subjects and rehabilitative strategies that harness cortical reorganization of motor function might be an option even in this chronically disabled subjects. Task oriented circuit training (TOCT) is an intensive task-specific intervention, for this reason we designed a pilot randomized-controlled trial: (i) to test the safety, feasibility and acceptability of a two weeks high-intensity task oriented circuit training in multiple sclerosis subjects with moderate gait impairments; (ii) to assess its preliminary effects on walking, mobility, fatigue and quality of life; (iii) to evaluate the adherence to a three months home based training program that followed TOCT; (iv) to determine TOCT effect sizes and the sample needed for a future RCT study.


                    This is a single-blind randomized controlled pilot trial. Subjects were recruited at the outpatient clinic of the Physical Medicine and Rehabilitation Department (Ferrara University Hospital). Informed written consent was obtained from eligible subjects. The research study has been reviewed and approved by the Ferrara University Hospital Ethics Committee and registered in ClinicalTrial.gov database (NCT01464749). The inclusion criteria were: males and females, age 18 to 75, diagnosis of MS (primary or secondary progressive, relapsing-remitting), without relapses in the preceding 3 months, mild to moderate gait impairments referred to Expanded Disability Status Scale (EDSS) score between 4 and 5.5. Subjects were able to walk for at least 100 meters with no constant assistance (cane, crutch or brace) required. The exclusion criteria were: other conditions that may affect motor function, impaired cognitive functioning (Mini Mental Status Examination score less than 24). Subjects were randomized to TOCT (experimental group) or usual care (control group) through a block randomization approach. Eligible subjects were randomly assigned into a 1:1 ratio to receive experimental treatment (task-oriented circuit training), or no specific treatment (usual care). The randomization scheme was generated by using the web site Randomization.com (http://​www.​randomization.​com). The experimental group received 10 task-oriented training sessions (Monday-Friday) over 2 weeks; each session lasted 2 hours. Control group did not receive any intervention.

                    Task-oriented circuit training

                    TOCT included six different workstations in which subjects exercised for 5 minutes in each one (3 minutes of exercises and 2 minutes of rest). During each session, subjects underwent 2 laps that took about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance was trained by 30 minutes walking on the treadmill including rests if necessary. For further details on training protocol see Table 1. This was a progressive circuit and subjects while exercising received feedbacks (visual and auditory) by the physiotherapist. Rests were used to discuss about difficulties and to provide further feedbacks. One session included up to 3 patients and lasted 120 minutes, 5 days/week for 2 weeks.
                    Table 1

                    Task-oriented circuit training description

                    Patients per group


                    N. of therapists

                    1 experienced physiotherapist

                    Intensity (I)

                    I: 2 weeks, 5 days per week, 120 minutes

                    Progression (P)

                    P: increasing the number of repetitions completed in 3 minutes at a workstation and increasing treadmill speed



                    1: Step (the patient goes up and down a 20 cm step both with left and right foot)

                    2: Slalom (the patient kicks a ball walking through a slalom exercise, formed by 4 cones that are 1 m distant from each other)

                    3: Tandem exercise (the patient walks in tandem using a line as a guide. If he/she is not able to put one foot in front of the other, it is allowed to do a wider and longer step as long as it is challenging)

                    4: Goals (the patient must touch with the tip of the foot a goal that is positioned on a mirror in front of him. If necessary, he can use a lateral support)

                    5: Obstacles (the patient must pass 5 obstacles, 3 of which are 5 cm high)

                    6: Long step (the patient must walk performing long steps (at least 40-50 cm long) using some signs on the floor as a guide)

                    Subjects exercise for 3 minutes at each workstation followed by a 2 minutes break

                    7: Treadmill (the patient should walk up to 30 minutes at speed between 0.9 and 2.9 km/h. The speed is self selected by the subject, who can also take a break if she/he needs to)

                    Home-based training program

                    After the supervised 2 weeks, a home- exercise illustrated brochure was given to subjects so that they could independently train for the following 3 months. It included similar exercises that subjects learned during the 2 weeks, gait training (overground or treadmill), stretching and strengthening exercises. We suggested an independent home training 3 times/week (60 minutes/each session). Our principal aim was to retain positive effects on walking competency and function. Subjects were asked to record in a diary the intensity and duration of exercise; they were allowed to call hospital to have further information and feedbacks.

                    Usual care (UC)

                    The control group (UC) did not receive any specific rehabilitation treatment for gait performance and mobility improvement.

                    During the entire study, both groups were authorized, at will, to exercise in non-rehabilitative contexts.

                    Outcome measures

                    Outcome measures were both functional tests (gait speed, walking endurance, mobility, balance) and self-reported questionnaires (fatigue, health-related quality of life and walking ability). All measures were assessed the week prior to treatment (T0), the week after the end of TOCT (T1) and the 3 months home-based training program (T2).

                    10 Meter Walk Test (10MWT)

                    It assesses walking speed over 10 meters. It has been tested on different kind of subjects (both with neurological and orthopaedics conditions), including MS [23, 24]. The subject walks in total for 14 meters: 2 m for acceleration and 2 m for deceleration, gait speed is calculated for the 10 m distance between them. The test is performed three times and best trial is used for analysis.

                    Six Minute Walk Test (SMWT)

                    Walking endurance was measured with SMWT, a feasible, reproducible and reliable measure in MS subjects [25]. Subjects were instructed to walk up and down a 20m walkway as far as possible in 6 minute.

                    Timed Up and Go test (TUG)

                    Subjects were given verbal instruction to stand up from a chair, walk 3 meters, cross a line marked on the floor, turn around, walk back, and sit down. Subjects performed 3 trials and their best performance was used for analysis [26].

                    Dynamic Gait Index (DGI)

                    It was developed as a clinical tool to assess gait, balance and risk of fall. It doesn’t evaluate only usual steady-state walking, but also walking during more challenging task (i.e. cross obstacles, slalom). Eight functional walking tests are performed by the subject and scored out of three (maximum total score is 24). Scores of 19 or less have been related to an increased risk of falls [27, 28].

                    Fatigue Severity Scale (FSS)

                    Fatigue was monitored through a questionnaire, Fatigue Severity Scale (FSS) which evaluates fatigue in MS and other conditions [29]. Essentially, the FSS consists of answering a short questionnaire that requires the subjects to rate their level of fatigue. Subjects were asked to read each statement and circle a number from 1 to 7, depending on how appropriate they felt the statement applied to them over the preceding week.

                    Multiple Sclerosis Walking Scale – 12 (MSWS-12)

                    This questionnaire assesses the impact of MS on walking ability. It is formed by 12 items, asking the patient about his perception on gait speed, running, confidence ascending/discending stairs, balance and fatigue. As in the MSIS 29, the total score is obtained by the sum of the score of each item (0-5) and then transformed into a value from 0 to 100. Again, a higher score represents a major walking disability [30].

                    Multiple Sclerosis Impact Scale – 29 (MSIS-29)

                    This is an health-rated quality of life questionnaire that assesses the impact of MS on physical and psychological functions. It is formed by 29 items on ADL I and II: 20 about physical activity and 9 of psychological status of the person. Each item can be scored with a value from 0 to 5; total score is given by the sum of all the items and then is transformed in a range from 0 to 100. A higher value correspond to a worse perception of subject’s HRQoL [31].

                    Feasibility patient-reported questionnaire

                    At the end of the 2 weeks, subjects who underwent TOCT received a questionnaire formed by twelve questions on their opinions and acceptability referred to the treatment received (for further details see Additional file 1).

                    Biostatistical analysis

                    Descriptive statistic (mean, median, standard deviation, percentiles and confidence interval) was used to describe sample at T0, T1, T2. Baseline characteristics (sex, age, MS type, MS duration, EDSS score) and clinical tests (SMWT, 10 mWT, TUG, DGI, FSS, MSIS-29 and MSWS-12) were compared among groups to assess the quality of randomization. Graphics frequency and Shapiro-Wilk Test were performed to assess variance in order to fulfill the essential assumptions for parametric statistical analysis for continuous variables. To try reducing Type I error, since variables were normally distributed, we choose ANOVA repeated measures for continuous variables (SMWT, 10 mWT and TUG) and Friedman test [32] for ordinal variables (DGI, MSIS-29 and MSWS-12, FSS) to test within-group differences. Post-hoc analysis have been performed when p < 0.05. Differences in mean changes from baseline (T0) after TOCT (T1) and 3 months home-based exercise (T2) were tested with un-paired t-test or Mann Whitney Test among groups. In order to calculate a sample size for a larger RCT, we used d (Cohen) [33]. An intention-to-treat analysis was carried out, i.e. in case of missing data (lost to follow-up) the last available value was considered (last observation carried forward approach). Statistical analysis was performed with STATA software, statistical software v12.1 college station, Texas. Significance level was set at 0.05.


                    Twenty-four PwMS have been assessed for eligibility in an outpatient rehabilitation clinic (Ferrara University Hospital). After the preliminary visit, all subjects (17 female, 7 male, age 52.58 ± 11.21, 15.21 ± 8.68 years from MS onset) were included in the study. They were randomized into groups: twelve were allocated to TOCT and twelve to UC. Demographic and clinical characteristics are summarized in Table 2. 37.5% of subjects received disease-modifying therapy (DMT) during the entire study (8.33% immunosuppressive treatments, 16.66% interferon beta, 4.16% glatiramer acetate and 8.33% fingolimod); 20.83% of them received therapies for MS symptoms management (i.e. spasticity, depression, pain). We didn’t report significant differences in DMT or symptomatic therapies among groups at baseline or any changes in pharmacological treatments during the study.All subjects completed the 2 weeks training, while we lost 3 subjects at 3 months follow-up in UC group. The clinical study flow-chart has been reported in Figure 1.
                    Table 2

                    Sample characteristics




                    All subjects



                    p value*






                    Gender (male/female)





                    MS type


















                    Mean (SD) median


                    All subjects



                    p value**

                    Age (years)

                    52.58 (11.21)

                    49.92 (7.51)

                    55.25 (13.82)






                    MS duration (years)

                    15.21 (8.68)

                    12.16 (6.91)

                    18.25 (9.46)






                    EDSS score

                    4.89 (0.54)

                    4.95 (0.61)

                    4.83 (0.49)






                    TOCT = task-oriented circuit training. UC = usual care. MS = multiple sclerosis. RR = relapsing remitting. PP = primary progressive. SP = secondary progressive. EDSS = Expanded Disability Status Scale.

                    *Pearson Chi-square.

                    **Mann-Whitney test.

                    Figure 1

                    Study flow diagram.

                    Functional tests (walking endurance, speed, balance, mobility)

                    A repeated-measures analysis of variance for SMWT, 10MWT and TUG and Friedman test for DGI revealed that TOCT and UC didn’t produce a significant improvement over time. Between-group differences were found in SMWT after TOCT (p < 0.05). Descriptive statistics are shown in Table 3.
                    Table 3

                    Clinical results


                    TOCT (n=12)


                    UC (n=12)


                    Mean (SD)

                    Median (25th-75th Percentile)

                    95% CI

                    Mean (SD)

                    Median (25th-75th Percentile)

                    95% CI

                    SMWT (m)


                    Pre- TOCT

                    290.67 (72.92)

                    283.40 (215.70 – 355.6)

                    244.33 – 337

                    285.72 (79.15)

                    298.40 (230.00 – 329.80)

                    235.42 – 336.01

                    Post- TOCT

                    310.72 (73.73)

                    316.20 (237.50 – 371.60)

                    263.87 – 357.57

                    275.77 (70.65)

                    293.40 (227.80 – 333)

                    230.88 – 320.66

                    3 months follow-up

                    301.03 (72.58)

                    308.50 (230.80 – 359.80)

                    254.92 – 347.15

                    258.73 (100.80)

                    274.30 (167.8 – 312.8)

                    194.69 – 322.78

                    TUG (s)


                    Pre- TOCT

                    10.64 (2.48)

                    9.89 (9.06 – 11.85)

                    9.06 – 12.21

                    12.10 (4.00)

                    11.19 (9.24 – 15)

                    9.56 – 14.63

                    Post- TOCT

                    10.05 (1.89)

                    9.55 (8.56 – 10.93)

                    8.85 – 11.25

                    12.23 (3.78)

                    11.61 (9.27 – 14.07)

                    9.82 – 14.63

                    3 months follow-up

                    10.50 (2.03)

                    9.56 (9.08 – 11.98)

                    9.20 – 11.78

                    12.43 (3.92)

                    12.25 (9.89 – 14.22)

                    9.94 – 14.93

                    10MWT (m/s)


                    Pre- TOCT

                    1.08 (0.23)

                    1.11 (0.94 – 1.20)

                    0.94 – 1.23

                    1.03 (0.30)

                    0.99 (0.77– 1.19)

                    0.84 – 1.22

                    Post- TOCT

                    1.13 (0.24)

                    1.10 (1.00 – 1.29)

                    0.98 – 1.28

                    1.02 (0.23)

                    1.03 (0.81 – 1.15)

                    0.87 – 1.16

                    3 months follow-up

                    1.15 (0.19)

                    1.19 (1.01 – 1.30)

                    1.02 – 1.27

                    0.99 (0.30)

                    0.87 (0.82 – 1.14)

                    0.80 – 1.19



                    Pre- TOCT

                    16.83 (3.56)

                    17 (15.5 – 19.5)

                    14.57 – 19.10

                    14.75 (4.92)

                    14 (12.5 – 18)

                    11.62 – 17.88

                    Post - TOCT

                    17.67 (3.11)

                    18 (16 – 20)

                    15.69 – 19.65

                    14.75 (4.14)

                    16 (12 – 18)

                    12.12 – 17.38

                    3 months follow-up

                    17.75 (3.93)

                    18 (14.5 – 10.5)

                    15.25 – 20.25

                    13.75 (3.86)

                    14 (11.5 – 17)

                    11.29 – 16.21

                    TOCT = task-oriented circuit training; UC = usual care; SMWT = Six Minute Walk Test; TUG = Timed Up and Go test; 10MWT = 10 Meter Walk Test; DGI = Dynamic Gait Index.

                    Patient-reported questionnaires (fatigue, walking ability, health-related quality of life)

                    MSIS-12 scores were improved in TOCT group (F(2,22) = 3.81, p < 0.05). MSIS-29 physical (F(2,22) = 3.66, p < 0.05) and psychological (F(2,22) = 3.55, p < 0.05) score improved in TOCT group and decreased in UC group (F(2,22) = 3.66, p < 0.05; F(2,22) = 4.28, p < 0.05) over time. Multiple comparisons were significant T0-T1 and T0-T2 in both groups. Between-group differences were found in MSWS-12 and MSIS-29 physical and psychological scores after TOCT (p < 0.01) and in MSIS-29 psychological score even after 3 months of home-based exercise (p < 0.05). Descriptive statistics are shown in Table 4.
                    Table 4

                    Questionnaire results


                    TOCT (n = 12)


                    UC (n = 12)


                    Mean (SD)

                    Median (25th-75th percentile)

                    95% CI

                    Mean (SD)

                    Median (25th-75th Percentile)

                    95% CI

                    MSIS-29 Psy (0-100)


                    Pre- TOCT

                    51.66 (20.61)

                    53.33 (32.22 – 64.44)

                    38.57 – 64.76

                    49.44 (20.12)

                    38.88 (36.11 – 72.22)

                    36.65 – 62.23

                    Post- TOCT

                    41.85 (15.73)

                    42.22 (30.00 – 46.66)

                    31.85 – 51.85

                    53.14 (19.24)

                    47.77 (40.00 – 72.77)

                    40.92 – 65.37

                    3 months follow-up

                    42.96 (16.20)

                    43.33 (29.44 – 56.11)

                    32.66 – 53.25

                    53.70 (16.43)

                    50.00 (42.77 – 65.00)

                    43.26 – 64.14

                    MSIS-29 Phys (0-100)


                    Pre- TOCT

                    50.83 (15.60)

                    53.00 (45.50 – 63.50)

                    40.92 – 60.74

                    51.58 (18.67)

                    50.00 (36.25 – 68.50)

                    39.71 – 63.44

                    Post- TOCT

                    44.41 (11.32)

                    43.00 (39.25 – 50.50)

                    37.22 – 51.61

                    53.75 (18.10)

                    52.00 (38.50 – 70.25)

                    42.24 – 65.25

                    3 months follow-up

                    49.16 (11.00)

                    48.00 (41.25 – 58.25)

                    42.17 – 56.15

                    53.00 (22.28)

                    49.00 (37.00 – 71.50)

                    38.83 – 67.16

                    MSWS-12 (0-100)


                    Pre- TOCT

                    63.06 (14.00)

                    66.67 (57.50 – 71.67)

                    54.16 – 71.95

                    61.94 (18.28)

                    60 (47.5 – 76.67)

                    50.33 – 73.56

                    Post- TOCT

                    52.36 (14.06)

                    53.33 (42.5 – 62.5)

                    43.43 – 61.29

                    70.83 (17.08)

                    75 (55 – 82.5)

                    59.98 – 81.68

                    3 months follow-up

                    65.42 (16.04)

                    63.33 (55 – 76.67)

                    55.23 – 75.61

                    71.11 (20.34)

                    74.17 (55.83 – 88.33)

                    58.19 – 84.04



                    Pre- TOCT

                    5.43 (1.23)

                    5.22 (4.94 – 6.50)

                    4.65 – 6.22

                    5.79 (0.98)

                    6.22 (4.77 –6.55)

                    5.17 – 6.42

                    Post- TOCT

                    5.05 (1.52)

                    5.44 (4.59 – 6.11)

                    4.09 – 6.02

                    6.11 (0.68)

                    6.11 (5.44 – 6.78)

                    5.68 – 6.54

                    3 months follow-up

                    5.63 (0.78)

                    5.78 (5.09 – 6.17)

                    5.13 – 6.13

                    6.01 (0.91)

                    6.28 (5.22 – 7)

                    5.51 – 6.66

                    TOCT = task-oriented circuit training; UC = usual care; MSIS-29 Psy and Phys = Multiple Sclerosis Impact Scale -29 (psychological and physical functions); MSWS-12 = Multiple Sclerosis Walking Scale – 12; FSS = Fatigue Severity Scale.

                    Feasibility patient-reported questionnaire

                    All subjects (n = 12) completed the questionnaire. On a Visual Analog Scale (VAS) 0-10 they reported a positive global rating on treatment received (9.1), considered the time duration adequate (8.5), the goals were achievable (7.6), the feedbacks provided during sessions were easy to understand (9.9), they enjoyed the training (8.4) and were satisfied by their own results (8.7). At the end of each session they felt physically tired (7), however they didn’t report the need of extra rests (0.25). The majority identified the treadmill (50%) as the exercise where they had best results whereas goals workstation (41.6%) where they had their worst; they considered slalom and tandem exercise workstation (25%) as much more enjoyable, while goals workstation as much more boring (33.33%).

                    Home based exercise adherence

                    At 3 months, 7/12 subjects (58.33%) completed their diary with home-exercise program and returned them to investigators. Considering the SMWT, we didn’t find further gains in subjects who completed the 3 months exercise program (good adherence sub-group) compared with subjects who didn’t report any information on their home exercise training (poor adherence sub-group). Specifically, at three months the good adherence sub-group (n = 7) decreased by -13.28 ± 6.72 m compared to post-TOCT, while the poor adherence sub-group (n = 5) of - 4.64 ± 32.37 m (n.s.).

                    Sample size calculation

                    Our preliminary results allowed us to define a sample size for a following RCT study. Considering walking endurance as primary outcome (SMWT), we found a TOCT effect size (d) of 0.85 in multiple sclerosis subjects (EDSS < 6). This value is based on a walking endurance improvement in TOCT group of 20.05 ± 25.06 m, compared to -9.95 ± 42.84 m in control group. Given equal allocation (1:1) between treatment and control arms, ad using 80% power and alpha of 5%, we would need 46 subjects (23 TOCT + 23 usual care) to complete the study. Conservatively, we expect a 10% rate of drop-out, thus the sample size will be increased by 10% to 51 subjects.


                    This is a proof-of-concept study with the aim of optimizing components of a novel rehabilitative intervention for PwMS with moderate mobility impairments. We proposed a high-intensity task-specific training which includes several principles of experience-dependent neuroplasticity such as specificity, repetition and intensity [18]; for this reason we hypothesized that a sample of PwMS with moderate mobility impairments might benefit from such intervention. Previous studies on TOCT highlighted positive effects on restoring mobility in stroke survivors including a wide range of exercise doses and intensities [16]. To our knowledge (except for treadmill, body-weight support treadmill and robot-assisted gait training [34]), the only attempts to apply a task-oriented training for mobility impairments in PwMS were done by Mark et al. [35] who proposed a Constraint-Induced Movement Therapy (CIMT) for the lower extremities and Salbach et al. [36] who tested a community exercise program for people with stroke, acquired brain injury and MS. CIMT was administered to a small sample (n = 4) showing positive effects on real-world lower extremity use up to four years. Compared to our TOCT, CIMT protocol was much more intense (3.5 h/d for 3 wk), trained 15 different tasks (compared to 7) and a “transfer package” to deliver gains into the real world was administered [35]. The community exercise program was delivered to 2 MS subjects twice/week for 12 weeks with no effects on walking endurance [36]. Our two weeks high-intensity task oriented circuit training was feasible and safe in a small group of PwMS with moderate mobility impairments. We didn’t report any injuries as a consequence of falls during TOCT sessions or marked fatigability which required the interruption of the exercise; all twelve subjects concluded the 10 sessions with no drop-outs. Furthermore, looking at the feasibility patient-reported questionnaire results, we might conclude that this is a suitable intervention in this population. To test TOCT effects on walking function we did both short-distance (10MWT) than long-distance (SMWT) walking tests in addition to a patient-reported measure of walking ability (MSWS-12). Long-distance walking test and patient-reported walking ability questionnaires were considered as the best measures to detect changes after rehabilitation in MS subjects [37]. Furthermore, long-distance walking tests, such as SMWT better reflect walking performance and functional capacity in MS population [38]. A good predictor for independency and mobility in PwMS is walking endurance measured by SMWT: it has been shown that subjects have 1% increased probability of being independent for every 1 m longer they walk during SMWT [23]. In our sample we didn’t find significant effects on gait speed measured with 10MWT probably because short-distance more than long-distance walking test are due to variability. In fact, a recent study reported a within-day variability of >20% for the 10MWT when baseline gait velocity was <1.2 m/s [39]. Another reason would be that we didn’t use the 25 foot walking test, which seems to be more reliable than 10MWT in detecting changes in PwMS [40]. Our findings in SMWT gains were close to the minimally important change from a patient prospective stated as 22 m [37]. In the same way MSWS-12 score improved by 11 points, showing beneficial effects on walking ability; this patient–reported outcome measure investigates limitation on walking abilities due to MS [30] and seems to be reliable in detecting changes after rehabilitation with a minimally important change of 10.39 points [37]. Considering how health-related quality of life is strongly reduced in PwMS [4], we found positive effects of TOCT on both physical and psychological functions in MSIS-29; however we have to consider how these results are within the standard error of the measurement which is defined as 5.3-9.5 points for physical domain and 7.6-13 points for psychological domain [41, 42]. Examining fatigue which is a common MS symptom with a negative impact on mobility, activities and quality of life, in our sample we didn’t find any detrimental effects of the task-oriented circuit training (2h/d over 2 weeks). Accordingly with previous studies [1012] we highlighted a slight fatigue reduction after TOCT. Nevertheless, these preliminary results should be taken cautiously, considering that this is a pilot study with the aim to test the safety and feasibility of a task-oriented circuit training in PwMS.

                    In our sample we found a lower adherence to home-exercise program (58%) compared to other studies in MS subjects [4345]. We can assume that giving a diary with a home-based exercise program wasn’t sufficient to motivate subjects to continue with task-oriented exercises at home. We can also speculate that task-oriented training is less suitable at home compared to other intervention tested in the aforementioned studies (mostly resistance exercises). Moreover, depression or cognitive symptoms, that are common in MS, might have reduced subjects’ compliance to rehabilitation, as clearly highlighted for MS medications [46]. However, we didn’t find any differences in walking endurance deterioration after TOCT among good- and poor-adherence subgroups.

                    Finally, as long walking tests are more appropriate in detecting clinically meaningful improvement after physical rehabilitation in MS population [37, 38], we calculated a sample size for a future RCT study based on the SMWT gains (51 subjects).

                    Limits and future directions

                    Our pilot study has several limitations. Firstly, our small and heterogeneous sample didn’t allow us to draw definite inferences from this analysis; moreover the inability to blind subjects’ on the treatments received (TOCT or UC) might have reduced the internal validity of the study; secondly, we didn’t use neither a valid method to address home-exercise adherence, nor psychiatric and neuropsychological evaluation to identify possible factors related to discontinued therapies; finally, we didn’t have real-world measures (i.e. accelerometer or step counters) to test transferability in everyday life.

                    Future directions: (i) to conduct a large RCT trial to confirm this preliminary results with a longer follow-up; (ii) to better explain MS mechanisms of functional recovery it would be necessary to add neuroimaging parameters (i.e. functional near-infrared spectroscopy); (iii) to quantify the dose of exercise delivered; (iv) to add real-world based measures (i.e. steps counters and specific patient-reported questionnaires); (v) to test TOCT in a wide range of mobility impairments (EDSS ≥ 6); (vi) to increase home-exercise program adherence with different methods (i.e. customized pamphlets, phone calls, physiotherapy visits).


                    In this pilot study, we assessed the safety, feasibility and preliminary effects on selected variables (gait speed, gait endurance, mobility, balance and health-related quality of life) of a task-oriented circuit training in a sample of multiple sclerosis subjects. Our main findings revealed that a 2 weeks task-oriented circuit training followed by a three months home exercise program is safe and well tolerated in multiple sclerosis subjects with moderate gait and mobility impairments. TOCT may allow a more intensive (more repetitions) and specific (task oriented) exercise in an enriched rehabilitative setting. No detrimental effects on subjective fatigue have been observed in this sample or major adverse effects (i.e. fall-related injury). Even though some positive effects on walking ability has been underlined, this trial cannot draw definitive conclusions on the effects of such intervention.



                    task-oriented circuit training


                    multiple sclerosis


                    Health-related quality of life


                    Expanded Disability Status Scale


                    People with multiple sclerosis


                    Usual care


                    10 Meter Walk Test


                    Six Minute Walk Test


                    Timed Up and Go Test


                    Dynamic Gait Index


                    Fatigue Severity Scale


                    Multiple Sclerosis Walking Scale – 12


                    Multiple Sclerosis Impact Scale


                    Disease-modifying therapy


                    Visual Analog Scale


                    Constraint – Induced Movement Therapy.



                    CM was supported by the Multiple Sclerosis Italian Society (grant 2010/R/6). CP and ASC were supported by Emilia Romagna region (grant 1786/2012). Thanks to Simonetta Masnada (PT) who delivered the task-oriented circuit training.

                    Authors’ Affiliations

                    Neuroscience and Rehabilitation Department, Ferrara University Hospital
                    Doctoral Program in Advanced Sciences and Technologies in Rehabilitation Medicine and Sports, Tor Vergata University
                    Physical Medicine and Rehabilitation Department, Istituto Ortopedico Rizzoli


                    1. Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430–1438.PubMedView Article
                    2. Sutliff MH: Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin 2010, 26:109–119.PubMedView Article
                    3. Pfaffenberger N, Pfeiffer K-P, Deibl M, Höfer S, Günther V, Ulmer H: Association of factors influencing health-related quality of life in MS. Acta Neurol Scand 2006, 114:102–108.PubMedView Article
                    4. Mitchell AJ, Benito-León J, González J-MM, Rivera-Navarro J: Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005, 4:556–566.PubMedView Article
                    5. Benedetti MG, Gasparroni V, Stecchi S, Zilioli R, Straudi S, Piperno R: Treadmill exercise in early mutiple sclerosis: a case series study. Eur J Phys Rehabil Med 2009, 45:53–59.PubMed
                    6. Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran J, Pickersgill TP, Morgan A: Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 70:174–179.PubMed CentralPubMedView Article
                    7. Van den Berg M, Dawes H, Wade DT, Newman M, Burridge J, Izadi H, Sackley CM: Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry 2006, 77:531–533.PubMed CentralPubMedView Article
                    8. Newman MA, Dawes H, van den Berg M, Wade DT, Burridge J, Izadi H: Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study. Mult Scler 2007, 13:113–119.PubMedView Article
                    9. Rietberg MB, Brooks D, Uitdehaag BMJ, Kwakkel G: Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005, CD003980.
                    10. Andreasen AK, Stenager E, Dalgas U: The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler 2011, 17:1041–1054.PubMedView Article
                    11. Gervasoni E, Cattaneo D, Jonsdottir J: Effect of treadmill training on fatigue in multiple sclerosis: a pilot study. Int J Rehabil Res 2014, 37:54–60.PubMedView Article
                    12. Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ: Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med 2013, 75:575–580.PubMedView Article
                    13. Latimer-Cheung AE, Martin Ginis KA, Hicks AL, Motl RW, Pilutti LA, Duggan M, Wheeler G, Persad R, Smith KM: Development of evidence-informed physical activity guidelines for adults with multiple sclerosis. Arch Phys Med Rehabil 2013, 94:1829–1836. e7PubMedView Article
                    14. Sá MJ: Exercise therapy and multiple sclerosis: a systematic review. J Neurol 2013. Epub ahead of print 22 Nov 2013. doi:10.1007/s00415–013–7183–9View Article
                    15. Lang CE, Macdonald JR, Reisman DS, Boyd L, Jacobson Kimberley T, Schindler-Ivens SM, Hornby TG, Ross SA, Scheets PL: Observation of amounts of movement practice provided during stroke rehabilitation. Arch Phys Med Rehabil 2009, 90:1692–1698.PubMed CentralPubMedView Article
                    16. English C, Hillier SL: Circuit class therapy for improving mobility after stroke. Cochrane Database Syst Rev 2010, CD007513.
                    17. Wevers L, van de Port I, Vermue M, Mead G, Kwakkel G: Effects of task-oriented circuit class training on walking competency after stroke: a systematic review. Stroke 2009, 40:2450–2459.PubMedView Article
                    18. Kleim JA, Jones TA: Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J Speech Lang Hear Res 2008, 51:S225-S239.PubMedView Article
                    19. Jang SH, Kim Y-H, Cho S-H, Lee J-H, Park J-W, Kwon Y-H: Cortical reorganization induced by task-oriented training in chronic hemiplegic stroke patients. Neuroreport 2003, 14:137–141.PubMedView Article
                    20. Tomassini V, Matthews PM, Thompson AJ, Fuglø D, Geurts JJ, Johansen-Berg H, Jones DK, Rocca MA, Wise RG, Barkhof F, Palace J: Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol 2012, 8:635–646.PubMed CentralPubMedView Article
                    21. Rocca MA, Colombo B, Falini A, Ghezzi A, Martinelli V, Scotti G, Comi G, Filippi M: Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005, 4:618–626.PubMedView Article
                    22. Tomassini V, Johansen-Berg H, Leonardi L, Paixão L, Jbabdi S, Palace J, Pozzilli C, Matthews PM: Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler 2011, 17:103–115.PubMed CentralPubMedView Article
                    23. Paltamaa J, Sarasoja T, Leskinen E, Wikström J, Mälkiä E: Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil 2007, 88:1649–1657.PubMedView Article
                    24. Dalgas U, Severinsen K, Overgaard K: Relations between 6 minute walking distance and 10 meter walking speed in patients with multiple sclerosis and stroke. Arch Phys Med Rehabil 2012, 93:1167–1172.PubMedView Article
                    25. Goldman MD, Marrie RA, Cohen JA: Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008, 14:383–390.PubMedView Article
                    26. Podsiadlo D, Richardson S: The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39:142–148.PubMed
                    27. Cattaneo D, Jonsdottir J, Repetti S: Reliability of four scales on balance disorders in persons with multiple sclerosis. Disabil Rehabil 2007, 29:1920–1925.PubMedView Article
                    28. Forsberg A, Andreasson M, Nilsagård YE: Validity of the dynamic gait index in people with multiple sclerosis. Phys Ther 2013, 93:1369–1376.PubMedView Article
                    29. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989, 46:1121–1123.PubMedView Article
                    30. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ: Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003, 60:31–36.PubMedView Article
                    31. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A: The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain J Neurol 2001,124(Pt 5):962–973.View Article
                    32. Conover WJ: Practical Nonparametric Statistics. 3rd edition. New York: John Wiley & Sons; 1999.
                    33. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988.
                    34. Swinnen E, Beckwée D, Pinte D, Meeusen R, Baeyens J-P, Kerckhofs E: Treadmill training in multiple sclerosis: can body weight support or robot assistance provide added value? A systematic review. Mult Scler Int 2012. Article ID 240274, 15 pages, 2012. doi:10.1155/2012/240274View Article
                    35. Mark VW, Taub E, Uswatte G, Bashir K, Cutter GR, Bryson CC, Bishop-McKay S, Bowman MH: Constraint-induced movement therapy for the lower extremities in multiple sclerosis: case series with 4-year follow-up. Arch Phys Med Rehabil 2013, 94:753–760.PubMedView Article
                    36. Salbach NM, Howe J-A, Brunton K, Salisbury K, Bodiam L: Partnering to Increase Access to Community Exercise Programs for People With Stroke, Acquired Brain Injury and Multiple Sclerosis. J Phys Act Health Epub ahead of print 13 May 2013
                    37. Baert I, Freeman J, Smedal T, Dalgas U, Romberg A, Kalron A, Conyers H, Elorriaga I, Gebara B, Gumse J, Heric A, Jensen E, Jones K, Knuts K, Maertens de Noordhout B, Martic A, Normann B, Eijnde BO, Rasova K, Santoyo Medina C, Truyens V, Wens I, Feys P: Responsiveness and Clinically Meaningful Improvement, According to Disability Level, of Five Walking Measures After Rehabilitation in Multiple Sclerosis: A European Multicenter Study. Neurorehabil Neural Repair Epub ahead of print 6 Feb 2014. doi:10.1177/1545968314521010
                    38. Gijbels D, Alders G, Van Hoof E, Charlier C, Roelants M, Broekmans T, Eijnde BO ‘t, Feys P: Predicting habitual walking performance in multiple sclerosis: relevance of capacity and self-report measures. Mult Scler 2010, 16:618–626.PubMedView Article
                    39. Feys P, Bibby B, Romberg A, Santoyo C, Gebara B, de Noordhout BM, Knuts K, Bethoux F, Skjerbæk A, Jensen E, Baert I, Vaney C, de Groot V, Dalgas U: Within-day variability on short and long walking tests in persons with multiple sclerosis. J Neurol Sci 2014, 338:183–187.PubMedView Article
                    40. Kieseier BC, Pozzilli C: Assessing walking disability in multiple sclerosis. Mult Scler 2012, 18:914–924.PubMedView Article
                    41. Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ: Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 2002, 73:701–704.PubMed CentralPubMedView Article
                    42. Learmonth YC, Hubbard EA, McAuley E, Motl RW: Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis. Qual Life Res Epub ahead of print 14 Feb 2014. doi:10.1007/s11136–014–0639–2 Epub ahead of print 14 Feb 2014. doi:10.1007/s11136-014-0639-2
                    43. Romberg A, Virtanen A, Ruutiainen J, Aunola S, Karppi S-L, Vaara M, Surakka J, Pohjolainen T, Seppänen A: Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. Neurology 2004, 63:2034–2038.PubMedView Article
                    44. Plow M, Bethoux F, McDaniel C, McGlynn M, Marcus B: Randomized controlled pilot study of customized pamphlets to promote physical activity and symptom self-management in women with multiple sclerosis. Clin Rehabil 2014, 28:139–148.PubMedView Article
                    45. DeBolt LS, McCubbin JA: The effects of home-based resistance exercise on balance, power, and mobility in adults with multiple sclerosis. Arch Phys Med Rehabil 2004, 85:290–297.PubMedView Article
                    46. Bruce JM, Hancock LM, Arnett P, Lynch S: Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010, 33:219–227.PubMedView Article
                    47. Pre-publication history

                      1. The pre-publication history for this paper can be accessed here: http://​www.​biomedcentral.​com/​1471-2377/​14/​124/​prepub


                    © Straudi et al.; licensee BioMed Central Ltd. 2014

                    This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.